Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors

American Journal of Obstetrics and Gynecology

Volumn 194, Issue 4, 2006, Pages 1119-1126

  Rice, Laurel W ^a   Stone, Rebecca L ^a   Xu, Miaohou ^a   Galgano, Mary ^b   Stoler, Mark H ^b   Everett, Elise N ^a   Jazaeri, Amir A ^a  

^a Norman Thornton Division of Gynecologic Oncology   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

AKT; Endometrial cancer; Malignant mixed m llerian tumor; mTOR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ENZYME INHIBITION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIXED TUMOR, MULLERIAN; ONCOGENE PROTEIN V-AKT;

EID: 33645881690     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.12.020     Document Type: Article

References (24)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 60 (1987) 2035-2041
3. Chambers S.K., Kapp D.S., Peschel R.E., Lawrence R., Merino M., Kohorn E.I., et al. Prognostic factors and sites of failure in FIGO stage I, grade 3 endometrial carcinoma. Gynecol Oncol 27 (1987) 180-188
4. Boronow R.C., Morrow C.P., Creasman W.T., Disaia P.J., Silverberg S.G., Miller A., et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63 (1984) 825-832
5. Sutton G.P., Geisler H.E., Stehman F.B., Young P.C., Kimes T.M., and Ehrlich C.E. Features associated with survival and disease-free survival in early endometrial cancer. Am J Obstet Gynecol 160 (1989) 1385-1391
6. Dinh T.V., Slavin R.E., Bhagavan B.S., Hannigan E.V., Tiamson E.M., and Yandell R.B. Mixed mullerian tumors of the uterus: a clinicopathologic study. Obstet Gynecol 74 (1989) 388-392
7. Nielsen S.N., Podratz K.C., Scheithauer B.W., and O'Brien P.C. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 34 (1989) 372-378
8. Schweizer W., Demopoulos R., Beller U., and Dubin N. Prognostic factors for malignant mixed mullerian tumors of the uterus. Int J Gynecol Pathol 9 (1990) 129-136
9. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22 (2004) 3902-3908
10. Risinger J.I., Hayes A.K., Berchuck A., and Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57 (1997) 4736-4738
11. Berchuck A. Biomarkers in the endometrium. J Cell Biochem Suppl 23 (1995) 174-178
12. Kohlberger P., Loesch A., Koelbl H., Breitenecker G., Kainz C., and Gitsch G. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 98 (1996) 151-155
13. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 (2000) 924-930
14. Salvesen H.B., Stefansson I., Kalvenes M.B., Das S., and Akslen L.A. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 94 (2002) 2185-2191
15. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
16. Martin M.B., Franke T.F., Stoica G.E., Chambon P., Katzenellenbogen B.S., Stoica B.A., et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141 (2000) 4503-4511
17. Zelmanowicz A., Hildesheim A., Sherman M.E., Sturgeon S.R., Kurman R.J., Barrett R.J., et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 69 (1998) 253-257
18. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 (1999) 1736-1744
19. Lukes A.S., Kohler M.F., Pieper C.F., Kerns B.J., Bentley R., Rodriguez G.C., et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73 (1994) 2380-2385
20. Hetzel D.J., Wilson T.O., Keeney G.L., Roche P.C., Cha S.S., and Podratz K.C. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47 (1992) 179-185
21. Riben M.W., Malfetano J.H., Nazeer T., Muraca P.J., Ambros R.A., and Ross J.S. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 10 (1997) 823-831
22. Slomovitz B.M., and Lu K.H. Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD.". Gynecol Oncol 92 (2004) 386-387
23. Kimura F., Watanabe J., Hata H., Fujisawa T., Kamata Y., Nishimura Y., et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 130 (2004) 161-168
24. Konopka B., Paszko Z., Janiec-Jankowska A., and Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett 178 (2002) 43-51